TCTMD Dr. Bhatt said that findings from the HEAT PPCI trial—suggesting that heparin alone is superior to bivalirudin in STEMI patients—“came as a surprise, and I don't have an immediate explanation for them.” But he cautioned that the only commonality ...
Drug Discovery & Development Treatment with bivalirudin (Angiox) was compared to heparin or low-molecular weight heparin (heparins) given with optional glycoprotein inhibitors (GPI). As reported in The New England Journal of Medicine last year, the trial met all of its pre ...
Pharmaceutical Online (press release) In the U.S., the drug is indicated as an anticoagulant in patients undergoing PCI with provisional use of GPI and in patients with, or at risk of, heparin -induced thrombocytopenia and thrombosis syndrome (HIT/HITTS) undergoing PCI. In Europe, Angiox is ...
HCPLive “Certain interventions such as emergency room observation units vs. hospital admission, rate control vs. rhythm control and use of low molecular weight heparin vs. unfractionated heparin have been previously described as potential means to reduce the ...
Medscape As previously reported by heartwire , the multicenter EUROMAX trial demonstrated that STEMI patients treated with bivalirudin had lower 30-day rates of death or...
TCTMD PARIS, France—In patients with ST-segment myocardial infarction (STEMI) being transported for primary percutaneous coronary intervention (PCI), upstream bivalirudin lowers mortality or major bleeding compared with heparin , an advantage that is ...
HealthCanal.com Las Vegas, Nev. — Two new studies that compared the safety and effectiveness of heparin and bivalirudin in percutaneous coronary intervention (PCI) will add fuel to the recent debate about the relative merits of the two anticoagulation medications, ...
